Minutes: Steering Board meeting, 15 January 2021

1. Moderna - Top up

The Members were reminded to indicate as soon as possible whether they wanted or not top-up doses for Moderna vaccine, and to indicate the wanted volume, as clarity was necessary on the overall top-up volume.

The Members were briefed about the details of the top-up offer (price) as well as the proposed schedule.

The Commission scheduled a Steering Board meeting with the representatives of Moderna, immediately after the ordinary SB so Members would have the possibility to seek for clarification to all their questions during this meeting.

Pfizer/BioNTech

In light of the rumours appeared on the same day regarding the Pfizer vaccine, the Commission organised a meeting after the SB meeting and .

It was agreed that the company needed to deliver a clear schedule with clear deliverables.

It was clarified that the top-up would need to be endorsed by a new contract, in order to comply with the procurement procedures.

As the interest of the MSs was high for the top up doses, the Commission stressed that the optional doses could be inserted in the contract.

The Member agreed to distribute the doses according to the prorata principle and to open optional top up

COVAX
The Commission representative informed 
WHO and COXAV 
that a contract with Pfizer for 
doses in 2021 of which around 
doses in 2021 of which around 

Some Members stressed that further discussions is necessary on how to manage the resale/donation in the current situation.

Regarding the donations, it was outlined that groups were targeted:

- Reselling or donating to LMICs through WHO/COVAX-
- Humanitarian aid for vulnerable people in non-deserved areas (refugee camps, conflict areas)

It was agreed that more concrete action was needed, therefore the MSs need to provide clarity regarding:

- which MSs would like to resell/donate, on which quantities and timeframe
- the number of doses each MSs would like to resell/donate.

The Commission underlined that the resell/donations needed to respect the contractual provisions of the APAs.

Implementation of the contracts
The Commission stressed that it was making all the efforts to solve the issues linked to the implementation of the contracts and delivery schedules.

Pfizer vaccine, the Commission organised a meeting after the SB meeting and 

Curevac - the Members were reminded that all the Order Forms needed to be sent by 22 January to the Commission.

Astra Zeneca - the company should send a delivery schedule. The Company suggested to organize a meeting on Wednesday only on logistics.

Moderna - the company asked from the MSs for a list with contacts of national transporters, to address possible issues regarding the transport.

Meeting with Moderna - on Top up doses
Moderna representatives stressed in their introductory remarks that:

- the company was expanding and made significant investments in Europe;
- the price proposed to the EU MSs was;
- the vaccine produced Moderna had a high efficiency rate (95%);
- the company had two similar sources of supply: EU and US;
- while the company would do its best to supply EU MSs from European production, the supply as fast as possible would be

The Commission clarified the value of the top up could impact the procedure.

The Company asked the MSs to indicate which of the three options submitted regarding the quantities would be retained by them.

The Company was informed that the Member States were still compiling the number of doses wanted which would provide a clearer idea on the overall volume in the course of the following week.

This would be communicated via a letter to the company immediately after.

**Meeting with BioNTech/Pfizer**

In order to urgently address the information appeared on the same days about the Pfizer deliveries, the Commission urgently convened a meeting between the company and the Steering Board.

Prior to the meeting with the MSs, the Commission:

- had informed the company about the fact that this situation;
- and
- solution

A preparatory SB meeting was held where almost all the Members, in a tour de table, reported that the local representatives of informed them on the same day.

Additionally, some MSs stressed that they had
During the meeting, almost all Member States intervened indicated that they were

Pfizer representatives explained that:

- the company had developed a plan that would allow the scale-up of manufacturing capacities in Europe and deliver significantly more doses;
- to accomplish this, certain modifications of production processes were required now. As a result,
- the company heard the Member States and proposed as a solution that
- beginning the week of January 25, with increased delivery beginning week of February 15;
- the company would inform about updated delivery schedules the European Commission, EU member states.